Home
Issues
2022
April 2022 Vol 12, No 2
March 2022 Vol 12 Special Feature
February 2022 Vol 12, No 1
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
ASCO Highlights
ASH Highlights
ESMO Highlights
SABCS Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Subscribe
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
JHOP Print Edition
We will request your mailing address on the next page.
JHOP E-Newsletters & Communications
TOP Print Edition
We will request your mailing address on the next page.
TOP E-Newsletters & Communications
I have reviewed and consent to the terms of
JHOP
's
Privacy Policy
, and
JHOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Home
Issues
2022
April 2022 Vol 12, No 2
March 2022 Vol 12 Special Feature
February 2022 Vol 12, No 1
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
ASCO Highlights
ASH Highlights
ESMO Highlights
SABCS Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
JHOP - February 2021 Vol 11, No 1
Case Reports
Original Article
From the Literature
FDA Oncology Update
ASH Highlights
Case Reports
Optimizing Response to Enasidenib with Dose Escalation in Relapsed or Refractory Acute Myeloid Leukemia
Amany R. Keruakous, MD; Sarah A. Schmidt, PharmD; Marcus T. Autry, PharmD; Julia Ye, PharmD Candidate; Phoi Nguyen, PharmD Candidate; Silas Day
Read More
Original Article
Optimizing Daratumumab Infusion: Assessing the Safety and Feasibility of Omitting Preinfusion Medications and Decreasing Infusion Time
Justine Preedit, PharmD; Anya Yudchyts, PharmD, BCOP
Read More
Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan
Ekim Ekinci, PharmD, MS, BCOP; James E. Cox, PharmD, BCOP; Joe E. Ensor, PhD; Edward T. McLean, PharmD, BCOP; Carlos A. Ramos, MD; Premal D. Lulla, MD; Rammurti T. Kamble, MD; George Carrum, MD
Read More
Evaluation of Infusion-Related and Hypersensitivity Reactions to Chemotherapy Over a Decade at a Community Cancer Center
Sarah Maryon Hayes, PharmD, BCOP; Jeremy Whalen, PharmD, BCOP; Nick Schutz, PharmD; Joseph Levine, MD
Read More
Electrolyte Abnormalities and the Associated Risk for Atrial Fibrillation After Autologous Hematopoietic Stem-Cell Transplant
Natalie Schulze, PharmD; Kyle LaPorte, PharmD; Carol Breikreutz, PharmD, BCOP; Tobias Meissner, PhD; R. Vinod Parameswaran, MD, FRCPath, MRCP; Renju Raj, MD; Kelly McCaul, MD, ABIM, FRCPC
Read More
From the Literature
Pembrolizumab Shows Long-Term Benefits in Patients with Metastatic Colorectal Cancer and MSI-H or dMMR
Read More
Sitagliptin, a DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant
Read More
FDA Oncology Update
FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations
Read More
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
Read More
Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations
Read More
Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients
Read More
FDA Approves Margenza for the Treatment of Metastatic HER2-Positive Breast Cancer
Read More
Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer
Read More
ASH Highlights
Meeting Highlights
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
Read More
Meeting Highlights
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
Read More
Meeting Highlights
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
Read More
Meeting Highlights
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
Read More
Meeting Highlights
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
Read More
Meeting Highlights
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
Read More
Privacy policy
Terms of Use
Home
About
Subscribe
Advertise
Contact Us
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.